MEDICAMENTOS EXCLUSIVOS CON PRINCIPIOS ACTIVOS OMALIZUMAB, SECUKINUMAB, RUXOLITINIB, ELTROMBOPAG, CANAKINUMAB, DABRAFENIB, TRAMETINIB, SIPONIMOD, EVEROLIMUS, OFATUMUMAB, LAPATINIB, DEXAMETASONA/TOBRAMICINA COLIRIO, ALPELISIB, NILOTINIB, PAZOPANIB, BASILIXIMAB, BROLUCIZUMAB Y RANIBIZUMAB JERINGA DEL LABORATORIO FARMACÉUTICO NOVARTIS FARMACEUTICA, S.A. DEL SERVICIOMURCIANO DE SALUD

Contract type	Supplies
CPV	33620000
Awarded to	NOVARTIS FARMACÉUTICA, S.A.

Full tender details, bidder list, market context and related contracts available below. Data sourced from TED — the Official Journal of the EU.